The drug-device combination becomes a complete therapy, and companies can see returns as early as the end of Phase II trials, Mr. Cima says. Although getting an FDA drug approval can be time-consuming and expensive, Mr. Cima says the payoff is greater. In some cases, medical device manufacturers can incorporate a drug that has already been approved in their device, he says.
Related Articles on Medical Devices:
FDA Extends Comment Period on 510(k) Document
World Sterilization Equipment and Supplies Market to Reach $3.31B by 2017
USC School of Pharmacy Establishes International Center for Regulatory Science
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
